-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

Benzinga·04/06/2026 13:20:29
Listen to the news
Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outperform and raises the price target from $21 to $23.